[1] SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi:  10.3322/caac.21660
[2] JIA W T, WANG L N. Using traditional Chinese medicine to treat hepatocellular carcinoma by targeting tumor immunity[J]. Evid Based Complement Alternat Med, 2020, 2020:9843486.
[3] WANG Y S, ZHANG Q F, CHEN Y C, et al. Antitumor effects of immunity-enhancing traditional chinese medicine[J]. Biomed Pharmacother, 2020, 121:109570. doi:  10.1016/j.biopha.2019.109570
[4] LIAO Y H, LIN C C, LAI H C, et al. Adjunctive traditional Chinese medicine therapy improves survival of liver cancer patients[J]. Liver Int, 2015, 35(12):2595-2602. doi:  10.1111/liv.12847
[5] ZHAI B T, ZHANG N N, HAN X M, et al. Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: a review[J]. Biomed Pharmacother, 2019, 114:108812. doi:  10.1016/j.biopha.2019.108812
[6] WANG X, YAN Y L, CHEN X, et al. The antitumor activities of Marsdenia tenacissima[J]. Front Oncol, 2018, 8:473. doi:  10.3389/fonc.2018.00473
[7] LIN J T, RUAN J Y, ZHU H, et al. Tenacissoside H induces autophagy and radiosensitivity of hepatocellular carcinoma cells by PI3K/Akt/mTOR signaling pathway[J]. Dose Response, 2021, 19(2): 15593258211011023.
[8] PAN Y T, LIAO X Y, YANG L L, et al. Extract of Marsdenia tenacissima (roxb.) moon[Apocynaceae]suppresses hepatocellular carcinoma by inhibiting angiogenesis[J]. Front Pharmacol, 2022, 13:900128. doi:  10.3389/fphar.2022.900128
[9] BOBYN J D, GLASSMAN A H, GOTO H, et al. The effect of stem stiffness on femoral bone resorption after canine porous-coated total hip arthroplasty[J]. Clin Orthop Relat Res, 1990(261):196-213.
[10] VEBER D F, JOHNSON S R, CHENG H Y, et al. Molecular properties that influence the oral bioavailability of drug candidates[J]. J Med Chem, 2002, 45(12):2615-2623. doi:  10.1021/jm020017n
[11] WANG P L, YANG J, ZHU Z F, et al. Marsdenia tenacissima: a review of traditional uses, phytochemistry and pharmacology[J]. Am J Chin Med, 2018: 1-32.
[12] LI S Y, PEI W H, ZHANG H. Simultaneous determination of eight bioactive components in Marsdenia tenacissima extract in rat plasma by LC-MS/MS and its application in a pharmacokinetic study[J]. Biomed Chromatogr, 2020, 34(11):e4946. doi:  10.1002/bmc.4946
[13] XIE B, LU Y Y, LUO Z H, et al. Tenacigenin B ester derivatives from Marsdenia tenacissima actively inhibited CYP3A4 and enhanced in vivo antitumor activity of paclitaxel[J]. J Ethnopharmacol, 2019, 235:309-319. doi:  10.1016/j.jep.2019.02.028
[14] XIA Z H, MAO S L, LAO A N, et al. Five new pregnane glycosides from the stems of Marsdenia tenacissima[J]. J Asian Nat Prod Res, 2011, 13(6):477-485. doi:  10.1080/10286020.2011.570263
[15] 康乐, 苗晋鑫, 方晓艳, 等. 基于网络药理学及分子对接的通关藤治疗非小细胞肺癌的现代机制[J]. 重庆理工大学学报(自然科学), 2021, 35(7):191-200.
[16] 覃薇, 殷梓辛, 华维维, 等. 基于网络药理学和分子对接探讨通关藤治疗胃癌的作用机制[J]. 实用临床医药杂志, 2022, 26(1):1-7,17.
[17] 肖雪峰, 张稳, 张新卓, 等. 药用植物通关藤研究进展[J]. 安徽农业科学, 2018, 46(9):19-21. doi:  10.13989/j.cnki.0517-6611.2018.09.006
[18] 张薇, 王泽锋, 王静, 等. 乌骨藤化学成分及其抗肿瘤活性[J]. 中成药, 2017, 39(2):334-338.
[19]

ZHAO J, LI H W, LI W Y, et al. Effects of sinapic acid combined with cisplatin on the apoptosis and autophagy of the hepatoma cells HepG2 and SMMC-7721[J]. Evid Based Complement Alternat Med, 2021, 2021:6095963.
[20]

ZHU G L, LIU X L, LI H J, et al. Kaempferol inhibits proliferation, migration, and invasion of liver cancer HepG2 cells by down-regulation of microRNA-21[J]. Int J Immunopathol Pharmacol, 2018, 32: 2058738418814341.
[21]

NAIR B, ANTO R J, M S, et al. Kaempferol-mediated sensitization enhances chemotherapeutic efficacy of sorafenib against hepatocellular carcinoma: an in silico and in vitro approach[J]. Adv Pharm Bull, 2020, 10(3):472-476. doi:  10.34172/apb.2020.058
[22]

MATHEW A A, ASIRVATHAM R, TOMY D V. Cardioprotective effect of Marsdenia tenacissima and Sansevieria roxburghiana in doxorubicin-induced cardiotoxicity in rats in vivo: the role of dresgenin and lupeol[J]. Turk J Pharm Sci, 2021, 18(3):271-281. doi:  10.4274/tjps.galenos.2020.27880
[23]

ZHANG Y Y, CHENG J X, ZHONG C, et al. ESR1 regulates the obesity- and metabolism-differential gene MMAA to inhibit the occurrence and development of hepatocellular carcinoma[J]. Front Oncol, 2022, 12:899969. doi:  10.3389/fonc.2022.899969
[24]

O'BRIEN M H, PITOT H C, CHUNG S H, et al. Estrogen receptor-α suppresses liver carcinogenesis and establishes sex-specific gene expression[J]. Cancers, 2021, 13(10):2355. doi:  10.3390/cancers13102355
[25]

MENG X Z, LIU X. Therapeutic value of estrogen receptor α in hepatocellular carcinoma based on molecular mechanisms[J]. J Clin Transl Hepatol, 2022, 10(1):140-146. doi:  10.14218/JCTH.2021.00224
[26]

WANG L B, CUI M X, CHENG D M, et al. MiR-9-5p facilitates hepatocellular carcinoma cell proliferation, migration and invasion by targeting ESR1[J]. Mol Cell Biochem, 2021, 476(2):575-583. doi:  10.1007/s11010-020-03927-z
[27]

CHEN F, NI X Y, CHEN L X, et al. MiR-939-3p promotes epithelial-mesenchymal transition and may be used as a prognostic marker in hepatocellular carcinoma[J]. Oncol Lett, 2020, 19(4):2727-2732.
[28]

KAO J T, LAI H C, TSAI S M, et al. Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients[J]. Liver Int, 2012, 32(6):928-936. doi:  10.1111/j.1478-3231.2011.02742.x
[29]

HE G B, DHAR D, NAKAGAWA H, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling[J]. Cell, 2013, 155(2):384-396. doi:  10.1016/j.cell.2013.09.031
[30]

KAMPAN N C, XIANG S D, MCNALLY O M, et al. Immunotherapeutic interleukin-6 or interleukin-6 receptor blockade in cancer: challenges and opportunities[J]. Curr Med Chem, 2018, 25(36):4785-4806. doi:  10.2174/0929867324666170712160621
[31]

ROSTAMI A, BALUCHNEJADMOJARAD T, ROGHANI M. Sinapic acid ameliorates paracetamol-induced acute liver injury through targeting oxidative stress and inflammation[J]. Mol Biol Rep, 2022, 49(6):4179-4191. doi:  10.1007/s11033-022-07251-1
[32]

QIU Z P, ZHANG C, ZHOU J X, et al. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade[J]. Mol Carcinog, 2019, 58(1):31-41. doi:  10.1002/mc.22904
[33]

HU J W, CHEN B, ZHANG J, et al. Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of hepatocellular carcinoma[J]. J Cancer, 2020, 11(21):6437-6444. doi:  10.7150/jca.47532
[34]

LI J J, ZHANG Y, HAN L W, et al. Tenacissoside H exerts an anti-inflammatory effect by regulating the nf-κb and p38 pathways in zebrafish[J]. Fish Shellfish Immunol, 2018, 83:205-212. doi:  10.1016/j.fsi.2018.09.032
[35]

GU F M, LI Q L, GAO Q, et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma[J]. Mol Cancer, 2011, 10:150. doi:  10.1186/1476-4598-10-150
[36]

LI J, LAU G K, CHEN L L, et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression[J]. PLoS One, 2011, 6(7):e21816. doi:  10.1371/journal.pone.0021816
[37]

ZHENG Q Q, MARTIN R C, SHI X J, et al. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling[J]. Theranostics, 2020, 10(22):9923-9936. doi:  10.7150/thno.45988
[38]

WANG J C, LU L B, LUO Z J, et al. MiR-383 inhibits cell growth and promotes cell apoptosis in hepatocellular carcinoma by targeting IL-17 via STAT3 signaling pathway[J]. Biomed Pharmacother, 2019, 120:109551. doi:  10.1016/j.biopha.2019.109551
[39]

MA H Y, YAMAMOTO G, XU J, et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease[J]. J Hepatol, 2020, 72(5):946-959. doi:  10.1016/j.jhep.2019.12.016
[40]

LI S Y, PEI W H, YUAN W, et al. Multi-omics joint analysis reveals the mechanism of action of the traditional Chinese medicine Marsdenia tenacissima (Roxb.) Moon in the treatment of hepatocellular carcinoma[J]. J Ethnopharmacol, 2022, 293:115285. doi:  10.1016/j.jep.2022.115285
[41]

TAN W L, LUO X, LI W D, et al. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma[J]. EBioMedicine, 2019, 40:446-456. doi:  10.1016/j.ebiom.2018.12.047
[42]

MA W J, CHEN X, WU X L, et al. Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway[J]. J Cell Physiol, 2020, 235(11):7849-7862. doi:  10.1002/jcp.29438
[43]

PARK E J, LEE J H, YU G Y, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression[J]. Cell, 2010, 140(2):197-208. doi:  10.1016/j.cell.2009.12.052
[44]

HEISSIG B, HATTORI K, DIAS S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand[J]. Cell, 2002, 109(5):625-637. doi:  10.1016/S0092-8674(02)00754-7
[45]

SUN S J, WANG N, SUN Z W, et al. MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9[J]. Eur Rev Med Pharmacol Sci, 2018, 22(15):4869-4878.
[46]

LIU P, XU D W, LI R T, et al. A combined phytochemistry and network pharmacology approach to reveal potential anti-NSCLC effective substances and mechanisms in Marsdenia tenacissima (roxb.) moon (stem)[J]. Front Pharmacol, 2021, 12:518406. doi:  10.3389/fphar.2021.518406